{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T21:06:31Z","timestamp":1779570391539,"version":"3.53.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116681","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:33:21Z","timestamp":1773826401000},"page":"116681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Geneo study: Comprehensive genomic profiling versus limited local reimbursed NGS panels within the belgian Precision initiative"],"prefix":"10.1016","volume":"240","author":[{"given":"Gordana Raiceivc","family":"Toungouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Hebrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Nannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Van Marcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Maetens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lore","family":"Decoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Demey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Collignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemie","family":"Rutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Vanden","family":"Bempt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Vermeij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Tejpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc.","family":"Canon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Van den Mooter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Lybaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni","family":"Van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"D\u2019Haene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Mebis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Van den Bulcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"De Greve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2026.116681_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101021","article-title":"Evaluation of personalized cancer therapies based on comprehensive genomic profiling in a middle-sized oncologic center in Austria, the University Clinic Krems","volume":"14","author":"Singer","year":"2021","journal-title":"Transl Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116681_bib2","first-page":"525","article-title":"Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors","volume":"7","author":"Cobain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116681_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100524","article-title":"PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment","volume":"7","author":"Thouvenin","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-025-00858-0","article-title":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer","volume":"9","author":"Volders","year":"2025","journal-title":"Npj Precis Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116681_bib5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ejca.2026.116681_bib6","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.3390\/cancers14102457","article-title":"Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors","volume":"14","author":"Froyen","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ejca.2026.116681_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116681_bib8","article-title":"The Belgian next generation sequencing guidelines for haematological and solid tumours","author":"H\u00e9brant","year":"2017","journal-title":"BJMO"},{"issue":"5","key":"10.1016\/j.ejca.2026.116681_bib9","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41591-025-03613-x","article-title":"Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial","volume":"31","author":"Tr\u00e9dan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116681_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.895729","article-title":"Prognostic and Predictive Value of CCND1\/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis","volume":"13","author":"Jeffreys","year":"2022","journal-title":"Front Endocrinol"},{"issue":"20","key":"10.1016\/j.ejca.2026.116681_bib11","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116681_bib12","article-title":"Comprehensive Review on the Clinical Impact of Next-Generation Sequencing Tests for the Management of Advanced Cancer","volume":"7","author":"Gibbs","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib13","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ejca.2026.116681_bib14","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13073-021-00897-9","article-title":"Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial","volume":"13","author":"Bertucci","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2026.116681_bib16","doi-asserted-by":"crossref","first-page":"S1202","DOI":"10.1016\/j.annonc.2024.08.2245","article-title":"LBA7 The Rome trial from histology to target: The road to personalize targeted therapy and immunotherapy","volume":"35","author":"Botticelli","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116681_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110465","article-title":"Molecular Tumor board for unicorns: outcomes for rare and ultra-rare cancers using an n-of-one personalized treatment strategy","volume":"27","author":"Louie","year":"2024","journal-title":"iScience"},{"issue":"10452","key":"10.1016\/j.ejca.2026.116681_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41698-022-00309-0","article-title":"Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy","volume":"6","author":"Louie","year":"2022","journal-title":"Npj Precis Oncol"},{"key":"10.1016\/j.ejca.2026.116681_bib20","article-title":"Clinical Outcomes of Molecular Tumor Boards: A Systematic Review","volume":"5","author":"Larson","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116681_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1604033","article-title":"Biomarker tests for molecularly targeted therapies--the key to unlocking precision medicine","volume":"375","author":"Lyman","year":"2016","journal-title":"NEnglJMed"},{"issue":"5","key":"10.1016\/j.ejca.2026.116681_bib23","first-page":"601","article-title":"Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective","volume":"25","author":"Reitsma","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"10.1016\/j.ejca.2026.116681_bib24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ijc.34753","article-title":"Differences in time to patient access to innovative cancer medicines in six European countries","volume":"154","author":"Vancoppenolle","year":"2024","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2026.116681_bib25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116681_bib26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116681_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102041","article-title":"Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study","volume":"8","author":"Joris","year":"2023","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.ejca.2026.116681_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","article-title":"Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116681_bib29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.annonc.2025.04.004","article-title":"Copenhagen Prospective Personalized Oncology (CoPPO)\u2014impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting","volume":"36","author":"Belcaid","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116681_bib30","article-title":"Spiderweb model and the Oncodistinct Network: Innovative organization of precision oncology clinical trials","author":"Awada","year":"2023","journal-title":"Present Phases Pr\u00e9coces Meet"},{"issue":"7776","key":"10.1016\/j.ejca.2026.116681_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2026.116681_bib32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2340\/1651-226X.2024.34885","article-title":"The evolution of precision oncology: the ongoing impact of the Drug Rediscovery Protocol (DRUP)","volume":"63","author":"Haj Mohammad","year":"2024","journal-title":"Acta Oncol"},{"issue":"16_","key":"10.1016\/j.ejca.2026.116681_bib33","article-title":"Impact of turnaround time (TAT) of molecular testing on initial treatment (Tx) in newly diagnosed stage 4 non-small cell lung cancer (NSCLC 4): An Integra Connect (IC) retrospective observational study","volume":"40","author":"Gart","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116681_bib34","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/curroncol31030115","article-title":"Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre","volume":"31","author":"Fleming","year":"2024","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.36401\/JIPO-24-11","article-title":"Usefulness of Comprehensive Genomic Profiling in Clinical Decision-Making in Oncology: A Systematic Review","volume":"8","author":"Limaye","year":"2025","journal-title":"J Immunother Precis Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jalm\/jfad091","article-title":"Clinical utility and benefits of comprehensive genomic profiling in cancer","volume":"9","author":"Tjota","year":"2024","journal-title":"J Appl Lab Med"},{"issue":"12","key":"10.1016\/j.ejca.2026.116681_bib37","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1038\/s41591-025-04061-3","article-title":"Determining the value of genomics in healthcare","volume":"31","author":"Goranitis","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116681_bib38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jval.2024.11.014","article-title":"A standardized measurement and valuation scale of genomic utility for policy decisions: the GUV Scale","volume":"28","author":"Goranitis","year":"2025","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.ejca.2026.116681_bib39","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3390\/cancers11122030","article-title":"Standardization of somatic variant classifications in solid and haematological tumours by a two-level approach of biological and clinical classes: an initiative of the Belgian ComPerMed Expert Panel","volume":"11","author":"Froyen","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of american pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn JMD"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib41","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1038\/s41467-025-60369-1","article-title":"Tissue-agnostic cancer therapies: promise, reality, and the path forward","volume":"16","author":"Subbiah","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116681_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104307","article-title":"Patients\u2019 selection and trial matching in early-phase oncology clinical trials","volume":"196","author":"Corbaux","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116681_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41698-025-00806-y","article-title":"A prospective pragmatic evaluation of automatic trial matching tools in a molecular tumor board","volume":"9","author":"Gueguen","year":"2025","journal-title":"Npj Precis Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T20:26:14Z","timestamp":1779567974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":43,"alternative-id":["S0959804926004612"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116681","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Geneo study: Comprehensive genomic profiling versus limited local reimbursed NGS panels within the belgian Precision initiative","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116682","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116681"}}